A Pilot, Multicenter, Open-Label, One-Group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS).

Trial Profile

A Pilot, Multicenter, Open-Label, One-Group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2012

At a glance

  • Drugs Acetylcysteine; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2009 Actual end date reported as June 2008 by ClinicalTrials.gov.
    • 23 May 2007 Status changed from in progress to completed.
    • 24 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top